U
IRMD icon

UBS’s iRadimed IRMD Stock Holding History

UBS’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$22K Buy
+3,136
New +$28.4K ﹤0.01% 7880

Other funds holding IRMD

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GMCM
Gruber & McBaine Capital Management San Francisco, California $369M AUM 12.23% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
CIS
Connors Investor Services Wyomissing, Pennsylvania $1.08B AUM 31.31% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

UBS's IRMD Position: Q3 2014 in Review

UBS opened a new position in iRadimed (IRMD) in Q3 2014: 3,136 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #7880 among its holdings.

17 funds tracked by Wall St. Rank hold IRMD as of Q3 2014.

  • UBS held 3,136 shares of iRadimed worth $22K as of Q3 2014.
  • iRadimed was a new UBS position in Q3 2014.
  • iRadimed made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7880 holding.
  • 17 funds tracked by Wall St. Rank held iRadimed as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.